Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2024 Jul 3.
Published in final edited form as: Chemistry. 2023 May 11;29(37):e202301141. doi: 10.1002/chem.202301141

Iodine(III)-Mediated Oxidation of Anilines to Construct Dibenzazepines

Carmen Margaret White [a], Naranchimeg Zorigt [a], Tianning Deng [a], Tom G Driver [a]
PMCID: PMC10330268  NIHMSID: NIHMS1892789  PMID: 37053500

Abstract

The development of an efficient process that produces bioactive medium-sized N-heterocyclic scaffolds from 2-substituted anilines using either iodosobenzene or (bis(trifluoroacetoxy)iodo)-benzene is reported. The tether between the sulfonamide and the aryl group can be varied to access dihydroacridine-, dibenzazepine-, or dibenzazocine scaffolds. While substitution on the aniline portion is limited to electron-neutral- or electron-poor groups, a broader range of functional groups are tolerated on the ortho-aryl substituent and site selective C─NAr bond formation can be achieved. Preliminary mechanistic investigations suggest that medium-ring formation occurs via radical reactive intermediates.

Keywords: dibenzazepine, dibenzazocine, oxidation, nitrogen-centered radical, medium-sized ring formation

Graphical Abstract

graphic file with name nihms-1892789-f0001.jpg

A mild, room temperature oxidative cyclization of 2-substituted anilines that accesses a broad range of medium-ring N-heterocycles via radical intermediates is reported.

Introduction

Despite their established and important bioactivity,[1] medium-sized N-heterocycles are underrepresented in pharmaceutical libraries.[2] Dibenzazepines and partially saturated dibenzazepines are important scaffolds,[3] which are found in the core of pharmaceutical agents, such as imipramine, eslicarbazepine acetate,[3e] and carbamazepine (Scheme 1). While this bioactivity has spurred the development of methods to ease their synthesis,[4],[5] the unfavorably high transition state energy barriers for medium-sized ring closure can limit the efficiency and selectivity of bond construction.[6] These weaknesses are illustrated in the common approaches to this scaffold, which involve either creating a C─C bond through a cross-coupling reaction, which requires pre-existing functionality and can afford a mixture of N-heterocyclic products,[5c, 5d] or a C─NAr bond through thermolysis of a symmetrical iminobibenzyl first reported by Thiele and Holzinger in 1899,[7] and is still widely employed for the synthesis of analogs.[8] This latter approach requires installation of functionality to occur post cyclization to differentiate the two sides of the dibenzazepine and can be non-selective.[9] The development of iodine(III)-mediated electrophilic aromatic substitution by the Muñiz-, Antonchick-, and other groups has emerged recently for the construction of C─NAr bonds using heteroaryl- or aryl amines as the nitrogen source.[10],[11] For example in 2011, Antonchick and co-workers reported a (diacetoxy)phenyliodine-mediated reaction between acetanilines (e.g. 9) and arenes that selectively afforded N,N-diaryl amines (e.g. 10).[11a] In 2020, we reported that benzazepinones could be synthesized from the room temperature oxidation of anilines that contain a strained ortho-cycloalkanol substituent,[12] and posited that the electrophilic nature of N-aryl nitrenoid triggered the ring-expansion-rearrangement sequence to provide 14. We were curious if this electrophilicity could be harnessed to enable the synthesis of dibenzazepines by trapping 16 with a pendant arene. If successful, this approach would enable the synthesis of differentially substituted dibenzazepines under mild conditions through the construction of a C─NAr from a C─H bond and address the weakness in the traditional approach to this scaffold that requires a symmetrical substrate.

Scheme 1.

Scheme 1.

Construction of the dibenzazepine scaffold.

Results and Discussion

To determine if dibenzazepines could be constructed from ortho-substituted anilines, the reactivity of 15 was investigated towards oxidants (Table 1). The substrate for our study was synthesized by a Heck cross-coupling reaction between 2-bromoaniline and styrene, followed by hydrogenation of the resulting stilbene, and terminating with a nitrogen-protection reaction. The optimization process began by submitting 15a (R = H) to iodosobenzene (PhIO) in hexafluoroisopropanol (HFIP) with 4 Å molecular sieves as an additive to remove the water byproduct because we found this combination of solvent and oxidant to be effective in promoting organoiodine-catalyzed oxidative cyclization-migration reactions.[13] In contrast to our previous work, a poor yield of 17a was observed (entry 1). We anticipated that the low yield of dibenzazepine 17a was due to product instability because only 44% of 17a remained when it was exposed to the oxidative reaction conditions.[14] Consequently, a series of N,N-disubstituted substrates were screened. While the use of N-alkyl or N-Boc substrates did not improve the yield of dibenzazepine (entries 2 and 3), changing the N-substituent to a more robust electron-withdrawing protecting group significantly increased the yield of the transformation to afford N-Ac 17d in 85% and N-Ts 17e in 88% (entries 4 and 5). Submission of trifluoroacetaniline 15f to reaction conditions, however, produced 17f in only 11% to suggest that the oxidative reaction is inhibited when too strong of an N-electron-withdrawing group is present (entry 6).[15] Hexafluoroisopropanol is critical to the success of the reaction:[16] changing the solvent severely attenuated the yield of dibenzoazepine 17e.[14] In attempt to increase the yield and reduce the reaction time, a stronger oxidant, PhI(O2CCF3)2 (PIFA) was investigated. Using this oxidant enabled the reaction time to be reduced to 30 minutes and still afforded dibenzazepine 17e in good yield (entry 7). Our next experiments focused on additives to further increase the yield of 17e. No improvement in the reaction outcome was observed with the addition of trifluoroacetic acid (entry 8). In contrast, the addition of magnesium oxide to eliminate the acid byproduct gave 17e in 95% in as little as 5 minutes (entry 9), and the yield remained 95% when the reaction was scaled to 1 mmol. While [hydroxy(tosyloxy)iodo]benzene (HTIB) produced 17e in great yield (entry 10), other oxidants screened (e.g. (diacetoxyiodo)-benzene (PIDA), Selectfluor, or m-CPBA) gave poor yields of dibenzazepine (entries 11 – 13). To determine if catalysis was possible, 15a was submitted to the conditions we identified to trigger 3H-indole formation (5 mol % PhI and 1.1 equiv of Selectfluor), but only 21% of 17e was observed (entry 14).[13] These investigations revealed that benzazepines could be smoothly formed using either PhIO and 4Å MS (entry 5) or PIFA and MgO (entry 9).

Table 1.

Development of optimal conditions for dibenzazepine formation.

graphic file with name nihms-1892789-t0006.jpg
entry # R oxidant (equiv) additivea time yield
17, %b
1 a H PhIO (1.1) 4Å MS 16 h 37
2 b iPr PhIO (1.1) 4Å MS 16 h 12
3 c Boc PhIO (1.1) 4Å MS 16 h 39
4 d Ac PhIO (1.1) 4Å MS 16 h 85
5 e Ts PhIO (1.1) 4Å MS 16 h 88
6 f TFA PhIO (1.1) 4Å MS 16 h 11
7 e Ts PhI(O2CCF3)2 (1.1) 0.5 h 73
8 e Ts PhI(O2CCF3)2 (1.1) TFA 5 min 72
9 e Ts PhI(O2CCF3)2 (1.1) MgO 5 min 95 (95)c
10 e Ts HTIB (1.1) MgO 0.3 h 92
11 e Ts PhI(O2CCH3)2 (1.1) MgO 5 min 22
12 e Ts Selectfluor (1.1) MgO 3 h 27
13 e Ts m-CPBA (1.1) MgO 10 h trace
14 e Ts PhI (0.05) Selectfluor (1.1) TFA 3 h 21
a

200 wt % of 4Å MS, 2 equiv of TFA, or 2 equiv of MgO added

b

As determined using 1H NMR spectroscopy using CH2Br2 as an internal standard.

c

Reaction performed using 1.00 mmol of 15e. HFIP = hexafluoroisopropanol; Ac = acetyl; Ts = tosyl; TFA = trifluoroacetic acid; HTIB = [hydroxy(tosyloxy)iodo]benzene; m-CPBA = meta-chloroperbenzoic acid.

The effect of changing the substituents on the aniline portion of 15 was investigated (Scheme 2). The impact of changing the electronic nature of the aryl amine was assayed by changing the identity of the R2- or R3-substituent. While significant decomposition was obtained with an electron-donating methoxy R2-group, the yield of dibenzazepine 17 increased as R2 became more electron-withdrawing. Aniline 15l, however, required the use of PhIO to minimize decomposition biproducts. To determine the effect of increasing the steric environment around either the nitrogen- or the ortho-phenethyl substituent, a methyl group was placed at either the R1- or R4-position. While increasing the steric environment around the nitrogen decreased the yield of 17p, the presence of an R4-methyl did not negatively affect the reaction outcome to provide 17q in 70% provided that PhIO was used.

Scheme 2.

Scheme 2.

Scope and limitations with regards to the aniline portion.

Next, changing the identity of the ortho-phenethyl substituent was surveyed (Scheme 3). In contrast to the reactivity of 15g, the addition of a methoxy substituent did not hinder the reaction: exposure of 15r to reaction conditions provided 17r in 94%. This reversal of the electronic preference was also observed in substrates that varied the identity of the 4-substituent; higher yields were observed with electron-donating substituents (e.g. 17r and 17s) than 15t bearing an electron-withdrawing 4-fluorine substituent. Our next investigations focused on the effect of changing the identity of the tether. While terphenyl amine 15u and methyl-substituted 15v were smoothly converted N-heterocycles 17u and 17v, benzoate 15w proved to be recalcitrant towards the reaction conditions. The length of the tether between the sulfonamide group and the aryl nucleophile was varied with 15x and 15y to determine if six- or eight-membered N-heterocycles could be constructed. The synthesis of dihydroacridine 17x and dibenzazocine 17y illustrates the generality of our method to create N-heterocycles irrespective of their ring-size. To determine if the reaction was site selective, 18a and 18b were subjected to reaction conditions to provide dibenzazepines as an 85:15 mixture of regioisomers. Improved selectivity was observed from dimethoxy-substituted 18c to provide a 96:4 mixture of dibenzazepines. The electronic nature of the aryl substituent was found to impact the site selectivity of the reaction: replacing the 3-OMe group with a fluorine resulted in a 98:2 mixture of 19d and 20d when 18d was submitted to reaction conditions.

Scheme 3.

Scheme 3.

Effect of changing the ortho-substituent identity on the reaction outcome.

Dibenzazepine formation could occur via the cyclization of radical- or cationic reactive intermediates (Scheme 4).[17] N-Iodination of 15e with PhIX2 generates intermediate 21. Homolysis of the C–N bond in 21 produces N-centered radical 22,[11f, 18] which cyclizes with the pendant arene to produce either spirocycle 23 through a 5-exo-trig cyclization or 24 through a kinetically less favorable 7-exo-trig cyclization.[19],[20] Oxidation of cyclohexadienyl radical 23 then produces 25. Alternatively, this spirocycle could be directly formed from nucleophilic attack of the arene on 21 or nitrenium ion 26, which could be produced from elimination of PhI from 21.[21] Ring-expansion of spirocycle would form 27,[22] which upon deprotonation forms dibenzazepine 17e.

Scheme 4.

Scheme 4.

Distinguishing between radical- or cation-mediated mechanisms.

To determine if radical intermediates were formed in the reaction, a series of experiments were executed (Scheme 4). When ambient light was rigorously excluded, the yield of the dibenzazepine formation was attenuated to 67%.[11f, 18a, 18b] The addition of radical traps proved to be more detrimental to the reaction outcome. The presence of TEMPO reduced the yield of 17e to 22%, and complete inhibition of the reaction was observed using BHT. Because the nucleophilicity of TEMPO and BHT can lead to spurious results,[23] 1,1-diphenylethylene (DPE) was investigated because it has been shown to be a better radical trap for iodine(III)-mediated reactions.[24],[25] Performing the reaction in the presence of DPE resulted in only decomposition being observed. Together these experiments suggest that dibenzazepine formation occurs via radical intermediates.

Conclusion

In conclusion, we have discovered a mild iodine(III)-mediated oxidation reaction to construct dibenzazepines. Our reaction requires only a slight excess of oxidant, tolerates a broad range of functionality, and is chemoselective for reaction with the pendant arene irrespective of its distance to the aryl amine. Our preliminary mechanistic investigations suggest that the reaction proceeds via radical intermediates, and our future work is aimed at further study of the mechanism and exploiting this reactivity to access other N-heterocycles.

Experimental Section

General procedure for PIFA-mediated oxidation.

To a solution of 2-substituted aniline (1.0 equiv) and magnesium oxide (2.0 equiv) in 1 mL of HFIP, a solution of [bis(trifluoroacetoxy)iodo]benzene (1.1 equiv) in 1 mL of HFIP was added dropwise over 5 minutes. Once visualization of the reaction progress using thin layer chromatography indicated that the starting material was consumed, the reactives were quenched by the addition of 3 mL of a H2O. The resulting mixture was extracted with 3 × 5 mL of EtOAc. The combined organic phases were dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo, and purification using MPLC (EtOAc:hexanes) afforded the product.

General procedure for PhIO-mediated oxidation.

To a mixture of 2-substituted aniline (1.0 equiv) and 4Å molecular sieves (200 wt %) in 1 mL of HFIP, a solution of iodosobenzene (1.1 equiv) in 1 mL of HFIP was added dropwise over 5 minutes. Once visualization of the reaction progress using thin layer chromatography indicated that the starting material was consumed, the reactives were quenched by the addition of 3 mL of a H2O. The resulting mixture was extracted with 3 × 5 mL of EtOAc. The combined organic phases were dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo, and the residue was analyzed using 1H NMR spectroscopy using CH2Br2 as the internal standard. Purification using MPLC (EtOAc:hexanes) afforded the product.

Supplementary Material

Suppinfo

Acknowledgments

We are grateful to the National Institutes of Health GM138388 for their generous financial support. We thank Mr. Furong Sun (UIUC) for high resolution mass spectrometry data.

References

  • [1].a) Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW, N. Engl. J. Med 2006, 354, 131–140; [DOI] [PubMed] [Google Scholar]; b) Lynch SM, Tafesse L, Carlin K, Ghatak P, Kyle DJ, Bioorg. Chem. Med. Lett 2015, 25, 43–47; [DOI] [PubMed] [Google Scholar]; c) Ji Ram V, Sethi A, Nath M, Pratap R, in The Chemistry of Heterocycles (Eds.: Ji Ram V, Sethi A, Nath M, Pratap R), Elsevier, 2019, pp. 393–425. [Google Scholar]
  • [2].Vitaku E, Smith DT, Njardarson JT, J. Med. Chem. 2014, 57, 10257–10274. [DOI] [PubMed] [Google Scholar]
  • [3].a) Gillman PK, Br. J. Pharmacol 2007, 151, 737–748; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Nelson DW, in Bioactive Heterocyclic Compound Classes (Eds.: Lamberth C, Dinges J), Wiley-VCH, 2012, pp. 115–133; [Google Scholar]; c) Di Fruscia P, Ho K-K, Laohasinnarong S, Khongkow M, Kroll SHB, Islam SA, Sternberg MJE, Schmidtkunz K, Jung M, Lam EWF, Fuchter MJ, MedChemComm 2012, 3, 373–378; [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Elliott E-C, Regan SL, Maggs JL, Bowkett ER, Parry LJ, Williams DP, Park BK, Stachulski AV, J. Med. Chem 2012, 55, 9773–9784; [DOI] [PubMed] [Google Scholar]; e) Lawthom C, Peltola J, McMurray R, Dodd E, Villanueva V, Neurol. Ther 2018, 7, 195–206; [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Watkins L, O'Dwyer M, Oak K, Lawthom C, Maguire M, Thomas R, Shankar R, Acta Neurol. Scand 2020, 142, 121–130; [DOI] [PubMed] [Google Scholar]; g) Pal R, Kumar B, Akhtar MJ, Chawla PA, Bioorg. Chem 2021, 115, 105230. [DOI] [PubMed] [Google Scholar]
  • [4].a) For reviews, see: Kricka LJ, Ledwith A, Chem. Rev 1974, 74, 101–123; [Google Scholar]; b) Kaur M, Garg S, Malhi SD, Sohal SH, Curr. Org. Chem 2021, 25, 449–506; [Google Scholar]; c) Bissember AC, Hyland CJT, Wales SM, Hawkins BC, Chen JLY, Fleming CL, Cording AP, Henneveld JS, Lo S, Zarfos SD, in Prog. Heterocycl. Chem , Vol. 33 (Eds.: Gribble GW, Joule JA), Elsevier, 2021, pp. 533–581; [Google Scholar]; d) Kuchkovska YO, Grygorenko OO, Comprehensive Heterocyclic Chemistry IV (Ed.: Rutjes FPJT), Elsevier, 2022, 49, 1–93. [Google Scholar]
  • [5].a) For representative approaches to the dibenzoazepine scaffold, see: Bergmann ED, Shahak I, Aisenshtat Z, Tetrahedron Lett. 1968, 9, 3469–3470; [Google Scholar]; b) Jørgensen TK, Andersen KE, Lau J, Madsen P, Huusfeldt PO, J. Heterocycl. Chem 1999, 36, 57–64; [Google Scholar]; c) Tsvelikhovsky D, Buchwald SL, J. Am. Chem. Soc 2010, 132, 14048–14051; [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Tsvelikhovsky D, Buchwald SL, J. Am. Chem. Soc 2012, 134, 16917–16917; [Google Scholar]; e) Christensen H, Schjøth-Eskesen C, Jensen M, Sinning S, Jensen HH, Chem. Eur. J 2011, 17, 10618–10627; [DOI] [PubMed] [Google Scholar]; f) Tsoung J, Panteleev J, Tesch M, Lautens M, Org. Lett 2014, 16, 110–113; [DOI] [PubMed] [Google Scholar]; g) Lam H, Tsoung J, Lautens M, J. Org. Chem 2017, 82, 6089–6099; [DOI] [PubMed] [Google Scholar]; h) Casnati A, Fontana M, Coruzzi G, Aresta BM, Corriero N, Maggi R, Maestri G, Motti E, Della Ca N, ChemCatChem 2018, 10, 4346–4352. [Google Scholar]
  • [6].a) Illuminati G, Mandolini L, Acc. Chem. Res 1981, 14, 95–102; [Google Scholar]; b) Wiberg KB, Angew. Chem., Int. Ed. Engl 1986, 25, 312–322; [Google Scholar]; c) Weinhold F, Nature 2001, 411, 539–541. [DOI] [PubMed] [Google Scholar]
  • [7].Thiele J, Holzinger O, Justus Liebigs Ann. Chem 1899, 305, 96–102. [Google Scholar]
  • [8].a) cf. Chaudhuri NK, Ball TJ, J. Labelled Compd. Radiopharm 1981, 18, 1189–1196; [Google Scholar]; b) Li W, You Q, Bioorg. Chem. Med. Lett 2007, 17, 3733–3735; [DOI] [PubMed] [Google Scholar]; c) Zhai J, You F, Xu S, Zhu A, Kang X, So Y-M, Shi X, Inorg. Chem 2022, 61, 1287–1296. [DOI] [PubMed] [Google Scholar]
  • [9].a) cf. Kricka LJ, Ledwith A, J. Chem. Soc., Perkin Trans 1 1973, 859–863; [Google Scholar]; b) Smith K, James DM, Mistry AG, Bye MR, Faulkner DJ, Tetrahedron 1992, 48, 7479–7488. [Google Scholar]
  • [10].a) For reviews, see: Samanta R, Matcha K, Antonchick AP, Eur. J. Org. Chem 2013, 2013, 5769–5804; [Google Scholar]; b) Narayan R, Manna S, Antonchick AP, Synlett 2015, 26, 1785–1803; [Google Scholar]; c) Murarka S, Antonchick AP, in Hypervalent Iodine Chemistry (Ed.: Wirth T), Springer International Publishing, Switzerland, 2016, pp. 75–104; [Google Scholar]; d) Muñiz K, in Hypervalent Iodine Chemistry , Vol. 373 (Ed.: Wirth T), Springer International Publishing, Switzerland, 2016, pp. 105–134; [Google Scholar]; e) Bering L, Manna S, Antonchick AP, Chem. Eur. J 2017, 23, 10936–10946; [DOI] [PubMed] [Google Scholar]; f) Bal A, Maiti S, Mal P, Chem. Asian J 2020, 15, 624–635; [DOI] [PubMed] [Google Scholar]; g) Singh FV, Shetgaonkar SE, Krishnan M, Wirth T, Chem. Soc. Rev 2022, 51, 8102–8139. [DOI] [PubMed] [Google Scholar]
  • [11].a) cf. Antonchick AP, Samanta R, Kulikov K, Lategahn J, Angew. Chem. Int. Ed 2011, 50, 8605–8608; [DOI] [PubMed] [Google Scholar]; b) Manna S, Serebrennikova PO, Utepova IA, Antonchick AP, Chupakhin ON, Org. Lett 2015, 17, 4588–4591; [DOI] [PubMed] [Google Scholar]; c) Haubenreisser S, Wöste TH, Martínez C, Ishihara K, Muñiz K, Angew. Chem. Int. Ed 2016, 55, 413–417; [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Lucchetti N, Scalone M, Fantasia S, Muñiz K, Adv. Synth. Catal 2016, 358, 2093–2099; [Google Scholar]; e) Fra L, Muñiz K, Chem. Eur. J 2016, 22, 4351–4354; [DOI] [PubMed] [Google Scholar]; f) Martínez C, Bosnidou AE, Allmendinger S, Muñiz K, Chem. Eur. J 2016, 22, 9929–9932; [DOI] [PubMed] [Google Scholar]; g) Mondal S, Samanta S, Jana S, Hajra A, J. Org. Chem 2017, 82, 4504–4510; [DOI] [PubMed] [Google Scholar]; h) Luan N, Liu Z, Han S, Shen L, Li J, Zou D, Wu Y, Wu Y, Tetrahedron Lett. 2020, 61, 151362; [Google Scholar]; i) Verma A, Singh Banjara L, Meena R, Kumar S, Asian J. Org. Chem 2020, 9, 105–110; [Google Scholar]; j) Morimoto K, Yanase K, Toda K, Takeuchi H, Dohi T, Kita Y, Org. Lett 2022, 24, 6088–6092. [DOI] [PubMed] [Google Scholar]
  • [12].Deng T, Mazumdar W, Ford RL, Jana N, Izar R, Wink DJ, Driver TG, J. Am. Chem. Soc 2020, 142, 4456–4463. [DOI] [PubMed] [Google Scholar]
  • [13].Deng T, Shi E, Thomas E, Driver TG, Org. Lett 2020, 22, 9102–9106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].See the Supporting Information for more details.
  • [15].The description of the electronic nature of the N-substituents surveyed came from their (or a closely related structual analog) Hammett σp-values (iPr −0.15; CO2Et 0.45; Ac 0.5; SO2Ph 0.68; TFA 0.80) listed in Hansch C, Leo A, Taft RW, Chem. Rev 1991, 91, 165–195. [Google Scholar]
  • [16].a) For a discussion of the positive and unique properties of hexafluoroisoproponal that enable oxidative reactions, see: Colomer I, Chamberlain AER, Haughey MB, Donohoe TJ, Nat. Rev. Chem 2017, 1, 0088; [Google Scholar]; b) Motiwala HF, Armaly AM, Cacioppo JG, Coombs TC, Koehn KRK, Norwood VMIV, Aubé J, Chem. Rev 2022, 122, 12544–12747. [DOI] [PubMed] [Google Scholar]
  • [17].a) Alternatively, dibenzazepine formation could occur through the oxidation of the ortho-phenethyl substituent, for mechanism studies of iodine(III)-oxidation of arenes, see: Nahakpam L, Chipem FAS, Chingakham BS, Laitonjam WS, Org. Biomol. Chem 2016, 14, 7735–7745; [DOI] [PubMed] [Google Scholar]; b) Jamsheena V, Mahesha CK, Joy MN, Lankalapalli RS, Org. Lett 2017, 19, 6614–6617; [DOI] [PubMed] [Google Scholar]; c) Harned AM, Org. Biomol. Chem 2018, 16, 2324–2329. [DOI] [PubMed] [Google Scholar]
  • [18].a) cf. Togo H, Hoshina Y, Muraki T, Nakayama H, Yokoyama M, J. Org. Chem 1998, 63, 5193–5200; [Google Scholar]; b) Martínez C, Muñiz K, Angew. Chem. Int. Ed 2015, 54, 8287–8291; [DOI] [PubMed] [Google Scholar]; c) Martínez C, Bosnidou AE, Allmendinger S, Muñiz K, Chem. Eur. J 2016, 22, 9929–9932; [DOI] [PubMed] [Google Scholar]; d) Kumar G, Pradhan S, Chatterjee I, Chem. Asian J 2020, 15, 651–672; [DOI] [PubMed] [Google Scholar]; e) Bosnidou AE, Romero RM, in Iodine Catalysis in Organic Synthesis (Eds.: Ishihara K, Muñiz K), Wiley-VCH: 2022, pp. 121–149. [Google Scholar]
  • [19].a) For a comparison of the rates of radical cyclizations, see: Griller D, Ingold KU, Acc. Chem. Res 1980, 13, 317–323; [Google Scholar]; b) Newcomb M, Tetrahedron 1993, 49, 1151–1176; [Google Scholar]; c) Musa OM, Horner JH, Shahin H, Newcomb M, J. Am. Chem. Soc 1996, 118, 3862–3868; [Google Scholar]; d) Buzlanova MM, Denisov ET, Kinet. Catal 2004, 45, 759–761; [Google Scholar]; e) Newcomb M, in Encyclopedia of Radicals in Chemistry, Biology and Materials, 2012. [Google Scholar]
  • [20].a) Acyl radicals, however, do engage in 7-exo-trig cyclizations, see: Boger DL, Mathvink RJ, J. Org. Chem 1988, 53, 3377–3379; [Google Scholar]; b) Evans PA, Roseman JD, J. Org. Chem 1996, 61, 2252–2253; [Google Scholar]; c) Chatgilialoglu C, Crich D, Komatsu M, Ryu I, Chem. Rev 1999, 99, 1991–2070; [DOI] [PubMed] [Google Scholar]; d) Ryu I, Miyazato H, Kuriyama H, Matsu K, Tojino M, Fukuyama T, Minakata S, Komatsu M, J. Am. Chem. Soc 2003, 125, 5632–5633. [DOI] [PubMed] [Google Scholar]
  • [21].a) Nitrenium ions have been posited as reactive intermediates in aerobic spirocyclizations, see: Wardrop DJ, Burge MS, Zhang W, Ortiz JA, Tetrahedron Lett. 2003, 44, 2587–2591; [Google Scholar]; b) Wardrop DJ, Burge MS, J. Org. Chem 2005, 70, 10271–10284; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Dohi T, Takenaga N, Fukushima K.-i., Uchiyama T, Kato D, Motoo S, Fujioka H, Kita Y, Chem. Commun 2010, 46, 7697–7699; [DOI] [PubMed] [Google Scholar]; d) Habert L, Cariou K, Angew. Chem. Int. Ed 2021, 60, 171–175. [DOI] [PubMed] [Google Scholar]
  • [22].a) For mechanistic studies of the ring-expansion of putative spiroindolenine reactive intermediates in the Pictet–Spengler reaction, see: Williams JR, Unger LR, J. Chem. Soc., Chem. Commun 1970, 1605–1606; [Google Scholar]; b) Jackson AH, Smith AE, Tetrahedron 1968, 24, 403–413; [Google Scholar]; c) Wu Q-F, Zheng C, You S-L, Angew. Chem., Int. Ed 2012, 51, 1680–1683; [DOI] [PubMed] [Google Scholar]; d) Wu Q-F, Zheng C, Zhuo C-X, You S-L, Chem. Sci 2016, 7, 4453–4459; [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Chambers SJ, Coulthard G, Unsworth WP, O'Brien P, Taylor RJK, Chem. Eur. J 2016, 22, 6496–6500; [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Zheng C, Xia Z-L, You S-L, Chem 2018, 4, 1952–1966; [Google Scholar]; g) Zheng C, You S-L, Acc. Chem. Res 2020, 53, 974–987. [DOI] [PubMed] [Google Scholar]
  • [23].cf. Kaschel J, Werz DB, Angew. Chem. Int. Ed 2015, 54, 8876–8878. [DOI] [PubMed] [Google Scholar]
  • [24].a) cf. Lubinkowski JJ, Knapczyk JW, Calderon JL, Petit LR, McEwen WE, J. Org. Chem 1975, 40, 3010–3015; [Google Scholar]; b) Pandit RP, Lee YR, Adv. Synth. Catal 2014, 356, 3171–3179; [Google Scholar]; c) Seo H, Katcher MH, Jamison TF, Nat. Chem 2017, 9, 453–456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].a) Stridfeldt E, Lindstedt E, Reitti M, Blid J, Norrby P-O, Olofsson B, Chem. Eur. J 2017, 23, 13249–13258; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Wang L, Zhao J, Sun Y, Zhang H-Y, Zhang Y, Eur. J. Org. Chem 2019, 2019, 6935–6944; [Google Scholar]; c) Zhang H, Shen J, Yang Z, Cui X, RCS Adv. 2019, 9, 7718–7722; [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Castoldi L, Di Tommaso EM, Reitti M, Gräfen B, Olofsson B, Angew. Chem. Int. Ed 2020, 59, 15512–15516. [DOI] [PMC free article] [PubMed] [Google Scholar]

Supporting Information

  • [26].Pangborn AB, Giardello MA, Grubbs RH, Rosen RK, Timmers FJ, Organometallics 1996, 15, 1518–1520. [Google Scholar]
  • [27].Lebedev AY, Izmer VV, Kazyul'kin DN, Beletskaya IP, Voskoboynikov AZ, Org. Lett 2002, 4, 623–626. [DOI] [PubMed] [Google Scholar]
  • [28].Shen M, Leslie BE, Driver TG, Angew. Chem. Int. Ed 2008, 47, 5056–5059. [DOI] [PubMed] [Google Scholar]
  • [29].Xia X-D, Xuan J, Wang Q, Lu L-Q, Chen J-R, Xiao W-J, Adv. Synth. Catal 2014, 356, 2807–2812. [Google Scholar]
  • [30].Li Y-L, Li J, Ma A-L, Huang Y-N, Deng J, J. Org. Chem 2015, 80, 3841–3851. [DOI] [PubMed] [Google Scholar]
  • [31].Jang YH, Youn SW, Org. Lett 2014, 16, 3720–3723. [DOI] [PubMed] [Google Scholar]
  • [32].Jiang Q, Duan-Mu D, Zhong W, Chen H, Yan H, Chem. Eur. J 2013, 19, 1903–1907. [DOI] [PubMed] [Google Scholar]
  • [33].Youn SW, Ko TY, Jang MJ, Jang SS, Adv. Synth. Catal 2015, 357, 227–234. [Google Scholar]
  • [34].Motoshima K, Noguchi-Yachide T, Sugita K, Hashimoto Y, Ishikawa M, Biorg. Med. Chem 2009, 17, 5001–5014. [DOI] [PubMed] [Google Scholar]
  • [35].Bowden BF, Read RW; Ritchie E, Taylor WC, Aust. J. Chem 1975, 28, 65. [Google Scholar]
  • [36].Sun K, Sachwani R, Richert KJ, Driver TG, Org. Lett 2009, 11, 3598–3601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Maier MS, Hüll K, Reynders M, Matsuura BS, Leippe P, Ko T, Schäffer L, Trauner D, J. Am. Chem. Soc 2019, 141, 17295–17304. [DOI] [PubMed] [Google Scholar]
  • [38].Okuzumi T, Ducker GS, Zhang C, Aizenstein B, Hoffman R, Shokat KM, Mol. BioSyst 2010, 6, 1389–1402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Husemoen G, Olsson R, Andersson C-M, Harvey SC, Hansen HC, J. Comb. Chem 2003, 5, 606–609. [Google Scholar]
  • [40].Nguyen Q, Sun K, Driver TG, J. Am. Chem. Soc 2012, 134, 7262–7265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Colabufo NA, Berardi F, Perrone R, Rapposelli S, Digiacomo M, Vanni M, Balsamo A, J. Med. Chem. 2008, 51, 1415–1422. [DOI] [PubMed] [Google Scholar]
  • [42].Schindler W, Gansser C, Therapeutically active derivatives of alkyleneamines. DE1960-GB31160 Application December 15, 1961, published DE1125438 March 15, 1962. [Google Scholar]
  • [43].Crisenza GEM, Sokolova OO, Bower JF, Angew. Chem. Int. Ed 2015, 54, 14866–14870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [44].Augurusa A, Mehta M, Perez M, Zhu J, Stephan DW, Chem. Commun 2016, 52, 12195–12198. [DOI] [PubMed] [Google Scholar]
  • [45].Yang F, Ding D, Wang C, Org. Lett 2020, 22, 9203–9209. [DOI] [PubMed] [Google Scholar]
  • [46].Gieshoff TN, Chakraborty U, Villa M, Jacobi von Wangelin A, Angew. Chem. Int. Ed 2017, 56, 3585–3589. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Suppinfo

RESOURCES